Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Youwei Bi

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pharmacology|December 3, 2022
Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare DiseasesRuo-Jing Li, Lian Ma, Fang Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2021
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLCErica C Nakajima, Nicole Drezner, Xiaoxue Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2021
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural MesotheliomaErica C Nakajima, Paz J Vellanki, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung CancerYufan Liu, Jeannette Nashed, Amy K Barone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2022
FDA Approval Summary: Cabozantinib for Differentiated Thyroid CancerElizabeth S Duke, Amy K Barone, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or FusionsJanice Kim, Diana Bradford, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other RearrangementsShruti U Gandhy, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade GliomaMichael I Barbato, Jeannette Nashed, Diana Bradford, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pharmacology|December 3, 2022
Model-Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare DiseasesRuo-Jing Li, Lian Ma, Fang Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2021
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLCErica C Nakajima, Nicole Drezner, Xiaoxue Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2021
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural MesotheliomaErica C Nakajima, Paz J Vellanki, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung CancerYufan Liu, Jeannette Nashed, Amy K Barone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2022
FDA Approval Summary: Cabozantinib for Differentiated Thyroid CancerElizabeth S Duke, Amy K Barone, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or FusionsJanice Kim, Diana Bradford, Erin Larkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other RearrangementsShruti U Gandhy, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade GliomaMichael I Barbato, Jeannette Nashed, Diana Bradford, et al.
Pageof 4